PTU-066 An “alcohol contract” has not reduced rates of post-transplant drinking following transplantation for alcoholic liver disease: Abstract PTU-066 Figure 1

Churg-Strauss Syndrome following PTU Treatment

Propylthiouracil (PTU) is a frequently prescribed drug in the treatment of hyperthyroidism. The use of PTU is, however, accompanied by numerous potentially serious side effects including vasculitis. PTU-related vasculitides can present as haematuria, pulmonary haemorrhage, or cutaneous lesion together with aspecific symptoms such as fever, myalgia, arthralgia, and fatigue. Cerebral involvement ...

Transplantation PTU-051 DONOR MORBIDITY FOLLOWING LIVING DONOR LIVER TRANSPLANTATION (LDLT): OUTCOME FROM A SMALL VOLUME CENTRE

Introduction Living Donor Liver Transplantation (LDLT) has grown immensely in certain countries over the last few years, whereas in West the growth remains static and low volume. Donor morbidity following LDLT has been reported in the median range of 15%e30% in various studies. One of the limiting factor for the growth of LDLT has been the concerns with morbidity and mortality during a centres ...

Liver transplantation in alcoholic patients: impact of an alcohol addiction unit within a liver transplant center.

BACKGROUND Many concerns about liver transplantation in alcoholic patients are related to the risk of alcohol recidivism. Starting from 2002, an Alcohol Addiction Unit (AAU) was formed within the liver transplant center for the management of alcoholic patients affected by end-stage liver disease and included in the waiting list for transplantation. We evaluated retrospectively the impact of the...

Alcohol Drinking Patterns and Nutrition in Alcoholic Liver Disease

Recurrence of fatty liver disease following liver transplantation for NAFLD-related cirrhosis: Current status and challenges

Non-alcoholic fatty liver disease (NAFLD) is emerging as a major health problem worldwide. NAFLD is a continuum of disease ranging from mild liver steatosis to severe steatohepatitis, which will ultimately lead to end-stage liver disease with high morbidity and mortality rates. This disorder is considered as a silent liver disease. The metabolic syndrome and its components are accounted as the ...